Non-alcoholic steatohepatitis: From cell biology to clinical practice

Journal of Hepatology

Volumn 44, Issue 1, 2006, Pages 197-208

  Cortez Pinto, Helena ^a,c   De Moura, Miguel Carneiro ^a   Day, Christopher Paul ^b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ASCORBIC ACID; BIOLOGICAL MARKER; CYTOKINE; FIBRIC ACID DERIVATIVE; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BARIATRIC SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLOGY; DIAGNOSTIC PROCEDURE; DIET THERAPY; DISEASE COURSE; ENDOPLASMIC RETICULUM; FIBROSIS; FOLLOW UP; HUMAN; INCIDENCE; INFORMATION; INSULIN RESISTANCE; KUPFFER CELL; LIFESTYLE; LIPID PEROXIDATION; LIVER CELL; LIVER FIBROSIS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; OXIDATION; OXIDATIVE STRESS; PATHOLOGY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

DISEASE PROGRESSION; FATTY LIVER; HUMANS; OXIDATIVE STRESS; PROGNOSIS; RISK FACTORS;

EID: 28844459409     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.09.002     Document Type: Conference Paper

References (126)

1. J.D. Browning, and J.D. Horton Molecular mediators of hepatic steatosis and liver injury J Clin Invest 114 2004 147 152
2. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2002 1221 1231
3. S. Bellentani, G. Bedogni, L. Miglioli, and C. Tiribelli The epidemiology of fatty liver Eur J Gastroenterol Hepatol 16 2004 1087 1093
4. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD. Single Topic Conference. Hepatology 2003;37:1202-19.
5. G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study Hepatology 42 2005 44 52
6. E.M. Brunt Nonalcoholic steatohepatitis: definition and pathology Semin Liver Dis 21 2001 3 16
7. Y. Falck-Ytter, Z.M. Younossi, G. Marchesini, and A.J. McCullough Clinical features and natural history of nonalcoholic steatosis syndromes Semin Liver Dis 21 2001 17 26
8. C.E. Ruhl, and J.E. Everhart Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States Gastroenterology 123 2003 745 750
9. J.M. Clark, F.L. Brancati, and A.M. Diehl The prevalence and etiology of elevated aminotransferase levels in the United States Am J Gastroenterol 98 2003 960 967
10. J.D. Browning, L.S. Szczepaniak, R. Dobbins, P. Nuremberg, J.D. Horton, and J.C. Cohen Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395
11. J.P. Ong, and Z.M. Younossi Nonalcoholic fatty liver disease (NAFLD) - two decades later: are we smarter about its natural history? Am J Gastroenterol 98 2003 1915 1917
12. E. Bugianesi, N. Leone, E. Vanni, G. Marchesini, F. Brunello, and P. Carucci Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma Gastroenterology 123 2002 134 140
13. C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Boparai, Y.C. Liu, and A.J. McCullough Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413 1419
14. L.A. Adams, J.F. Lymp, J. St Sauver, S.O. Sanderson, K.D. Lindor, and A. Feldstein The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 2005 113 121
15. C.P. Day Natural history of NAFLD: remarkably benign in the absence of cirrhosis Gastroenterology 129 2005 375 378
16. S. Dam-Larsen, M. Franzmann, I.B. Andersen, P. Christoffersen, L.B. Jensen, and T.I. Sorensen Long term prognosis of fatty liver: risk of chronic liver disease and death Gut 53 2004 750 755
17. L.A. Adams, S. Sanderson, K.D. Lindor, and P. Angulo The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies J Hepatol 41 2005 132 138
18. E.M. Brunt Nonalcoholic steatohepatitis Semin Liver Dis 24 2004 3 20
19. E.M. Brunt, C.G. Janney, A.M. Di Bisceglie, B.A. Neuschwander-Tetri, and B.R. Bacon Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 94 1999 2467 2474
20. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, and O.W. Cummings Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
21. G.A. Abrams, S.S. Kunde, A.J. Lazenby, and R.H. Clements Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease Hepatology 40 2004 475 483
22. S.H. Caldwell, and D.M. Crespo The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease J Hepatol 40 2004 578 584
23. J.M. Hui, J.G. Kench, S. Chitturi, A. Sud, G.C. Farrell, and K. Byth Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C Hepatology 38 2003 420 427
24. S. Ramesh, and A.J. Sanyal Evaluation and management of non-alcoholic steatohepatitis J Hepatol 42 Suppl 2005 S2 S12
25. P. Angulo, J.C. Keach, K.P. Batts, and K.D. Lindor Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis Hepatology 30 1999 1356 1362
26. V. Ratziu, F. Charlotte, A. Heurtier, S. Gombert, P. Giral, and E. Bruckert Sampling variability of liver biopsy in nonalcoholic fatty liver disease Gastroenterology 128 2005 1898 1906
27. A. Suzuki, P. Angulo, J. Lymp, D. Li, S. Satomura, and K. Lindor Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease Liver Int 25 2005 779 786
28. K. Patel, S.C. Gordon, I. Jacobson, C. Hezode, E. Oh, and K.M. Smith Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients J Hepatol 41 2004 935 942
29. T.B. Kelleher, S.H. Mehta, R. Bhaskar, M. Sulkowski, J. Astemborski, and D.L. Thomas Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index J Hepatol 43 2005 78 84
30. F. Imbert-Bismut, V. Ratziu, L. Pieroni, F. Charlotte, Y. Benhamou, and T. Poynard Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study Lancet 357 2001 1069 1075
31. C.T. Wai, J.K. Greenson, R.J. Fontana, J.D. Kalbfleisch, J.A. Marrero, and H.S. Conjeevaram A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 2003 518 526
32. W.M. Rosenberg, M. Voelker, R. Thiel, M. Becka, A. Burt, and D. Schuppan Serum markers detect the presence of liver fibrosis: a cohort study Gastroenterology 127 2004 1704 1713
33. M. Ziol, A. Handra-Luca, A. Kettaneh, C. Christidis, F. Mal, and F. Kazemi Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C Hepatology 41 2005 48 54
34. L. Castera, J. Vergniol, J. Foucher, B. Le Bail, E. Chanteloup, and M. Haaser Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C Gastroenterology 128 2005 343 350
35. P. Sathya, S. Martin, and F. Alvarez Nonalcoholic fatty liver disease (NAFLD) in children Curr Opin Pediatr 14 2002 593 600
36. A.W. Marion, A.J. Baker, and A. Dhawan Fatty liver disease in children Arch Dis Child 89 2004 648 652
37. E.A. Roberts Non-alcoholic fatty liver disease (NAFLD) in children Front Biosci 10 2005 2306 2318
38. J.B. Schwimmer, R. Deutsch, J.B. Rauch, C. Behling, R. Newbury, and J.E. Lavine Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease J Pediatr 143 2003 500 505
39. J.E. Lavine, and J.B. Schwimmer Nonalcoholic fatty liver disease in the pediatric population Clin Liver Dis 8 2004 549 558
40. C.P. Day, and O.F.W. James Steatohepatitis: a tale of two 'hits' Gastroenterology 114 1998 842 845
41. A.E. Feldstein, A. Canbay, P. Angulo, M. Taniai, L.J. Burgart, and K.D. Lindor Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 125 2003 437 443
42. D. Pessayre, A. Bearson, B. Fromenty, and A. Mansour Mitochondria in steatohepatitis Semin Liver Dis 21 2001 57 69
43. E. Albano, E. Mottaran, M. Vidali, E. Reale, S. Saksena, and G. Occhino Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis Gut 54 2005 987 993
44. E. Zamara, E. Novo, F. Marra, A. Gentilini, R.G. Romanelli, and A. Caligiuri 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells J Hepatol 40 2004 60 68
45. K.J. Moore, E.D. Rosen, M.L. Fitzgerald, F. Randow, L.P. Andersson, and D. Altshuler The role of PPAR-gamma in macrophage differentiation and cholesterol uptake Nat Med 7 2001 41 47
46. P.S. Ribeiro, H. Cortez-Pinto, S. Sola, R.E. Castro, R.M. Ramalho, and A. Baptista Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients Am J Gastroenterol 99 2004 1708 1717
47. I.A. Leclercq, G.C. Farrell, J. Field, D.R. Bell, F.J. Gonzalez, and G.R. Robertson CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis J Clin Invest 105 2000 1067 1075
48. P. Lettéron, B. Fromenty, B. Terris, C. Degott, and D. Pessayre Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice J Hepatol 24 1996 200 208
49. A.J. Sanyal, C. Campbell-Sargent, F. Mirshahi, W.B. Rizzo, M.J. Contos, and R.K. Sterling Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities Gastroenterology 120 2001 1183 1192
50. C. Garcia-Monzon, E. Martin-Perez, O.L. Iacono, M. Fernandez-Bermejo, P.L. Majano, and A. Apolinario Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity J Hepatol 33 2000 716 724
51. S. Seki, T. Kitada, T. Yamada, H. Sakaguchi, K. Nakatani, and K. Wakasa In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases J Hepatol 37 2002 56 62
52. S.C. Lu, L. Alvarez, Z.Z. Huang, L. Chen, W. An, and F.J. Corrales Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation Proc Natl Acad Sci USA 98 2001 5560 5565
53. S. Yang, H. Zhu, Y. Li, H. Lin, K. Gabrielson, and M.A. Trush Mitochondrial adaptations to obesity-related oxidant stress Arch Biochem Biophys 15 2000 259 268
54. G. Musso, R. Gambino, F. Michieli, and M. Cassader Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis Hepatology 37 2003 909 915
55. C.P. Day Pathogenesis of steatohepatitis Best Pract Res Clin Gastroenterol 16 2002 663 678
56. S. Nielsen, Z. Guo, C.M. Johnson, D.D. Hensrud, and M.D. Jensen Splanchnic lipolysis in human obesity J Clin Invest 113 2004 1582 1588
57. V.T. Samuel, Z.X. Liu, X. Qu, B.D. Elder, S. Bilz, and D. Befroy Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease J Biol Chem 279 2004 32345 32353
58. D. Cai, M. Yuan, D.F. Frantz, P.A. Melendez, L. Hansen, and J. Lee Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB Nat Med 11 2005 183 190
59. J.K. Reddy Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis Am J Physiol Gastrointest Liver Physiol 281 2001 G1333 G1339
60. E. Ip, G.C. Farrell, G. Robertson, P. Hall, R. Kirsch, and I. Leclercq Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice Hepatology 38 2003 123 132
61. D. Pessayre, and B. Fromenty NASH: a mitochondrial disease J Hepatol 42 2005 928 940
62. C.Y. Fan, J. Pan, N. Usuda, A.V. Yeldandi, M.S. Rao, and J.K. Reddy Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism J Biol Chem 273 1998 15639 15645
63. A. Laurent, C. Nicco, J. Tran Van Nhieu, D. Borderie, C. Chereau, and F. Conti Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis Hepatology 39 2004 1277 1285
64. S.H. Caldwell, R.H. Swerdlow, E.M. Khan, J.C. Iezzoni, E.E. Hespenheide, and J.K. Parks Mitochondrial abnormalities in non-alcoholic steatohepatitis J Hepatol 31 1999 430 434
65. H. Cortez-Pinto, J. Chatham, V.P. Chacko, C. Arnold, A. Rashid, and A.M. Diehl Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study J Am Med Assoc 282 1999 1659 1664
66. M. Perez-Carreras, P. Del Hoyo, M.A. Martin, J.C. Rubio, A. Martin, and G. Castellano Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis Hepatology 38 2003 999 1007
67. S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, and Y. Nakajima Increased oxidative stress in obesity and its impact on metabolic syndrome J Clin Invest 114 2004 1752 1761
68. S.P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, and A.W. Ferrante Jr Obesity is associated with macrophage accumulation in adipose tissue J Clin Invest 112 2003 1796 1808
69. D. Ron Translational control in the endoplasmic reticulum stress response J Clin Invest 110 2002 1383 1388
70. C. Ji, and N. Kaplowitz Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice Gastroenterology 124 2003 1488 1499
71. J.M. Lluis, A. Colell, C. Garcia-Ruiz, N. Kaplowitz, and J.C. Fernandez-Checa Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress Gastroenterology 124 2003 708 724
72. U. Ozcan, Q. Cao, E. Yilmaz, A.H. Lee, N.N. Iwakoshi, and E. Ozdelen Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes Science 306 2004 457 461
73. M.C. Arkan, A.L. Hevener, F.R. Greten, S. Maeda, Z.W. Li, and J.M. Long IKK-beta links inflammation to obesity-induced insulin resistance Nat Med 11 2005 191 198
74. J. Crespo, A. Cayon, P. Fernandez-Gil, M. Hernandez-Guerra, M. Mayorga, and A. Dominguez-Diez Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients Hepatology 34 2001 1158 1163
75. H. Nagai, K. Matsumaru, G. Feng, and N. Kaplowitz Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes Hepatology 36 2002 55 64
76. W.X. Ding, and X.M. Yin Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury J Cell Mol Med 8 2004 445 454
77. R.A. Kirkland, J.A. Windelborn, J.M. Kasprzak, and J.L. Franklin A Bax-induced pro-oxidant state is critical for cytochrome c release during programmed neuronal death J Neurosci 22 2002 6480 6490
78. M. Mari, A. Colell, A. Morales, C. Paneda, I. Varela-Nieto, and C. Garcia-Ruiz Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis J Clin Invest 113 2004 895 904
79. A.H. Merrill Jr, S. Lingrell, E. Wang, M. Nikolova-Karakashian, T.R. Vales, and D.E. Vance Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion J Biol Chem 270 1995 13834 13841
80. A. Colell, C. Garcia-Ruiz, M. Miranda, E. Ardite, M. Mari, and A. Morales Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor Gastroenterology 115 1998 1541 1551
81. A.E. Feldstein, N.W. Werneburg, A. Canbay, M.E. Guicciardi, S.F. Bronk, and R. Rydzewski Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway Hepatology 40 2004 185 194
82. S.Q. Yang, H.Z. Lin, M.D. Lane, M. Clemens, and A.M. Diehl Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis Proc Natl Acad Sci USA 94 1997 2557 2562
83. A.J. Wigg, I.C. Roberts-Thomson, R.B. Dymock, P.J. McCarthy, R.H. Grose, and A.J. Cummings The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis Gut 48 2001 206 211
84. K.E. Wellen, and G.S. Hotamisligil Obesity-induced inflammatory changes in adipose tissue J Clin Invest 112 2003 1785 1788
85. C.P. Day, N.F. deSilva, A.L. Harte, P.G. McTernan, and S. Kumar Chronic endotoxinaemia in NAFLD: a potential role in the development of insulin resistance/diabetes and in liver disease progression J Hepatol 42 (suppl) 2005 25
86. T. Yamauchi, J. Kamon, H. Waki, Y. Terauchi, N. Kubota, and K. Hara The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity Nat Med 7 2001 941 946
87. N. Maeda, I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, and H. Nagaretani Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 Nat Med 8 2002 731 737
88. A. Xu, Y. Wang, H. Keshaw, L.Y. Xu, K.S. Lam, and G.J. Cooper The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice J Clin Invest 112 2003 91 100
89. J.M. Hui, A. Hodge, G.C. Farrell, J.G. Kench, A. Kriketos, and J. George Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40 2004 46 54
90. S. Kaser, A. Moschen, A. Cayon, A. Kaser, J. Crespo, and F. Pons-Romero Adiponectin and its receptors in non-alcoholic steatohepatitis Gut 54 2005 117 121
91. A. Canbay, P. Taimr, N. Torok, H. Higuchi, S. Friedman, and G.J. Gores Apoptotic body engulfment by a human stellate cell line is profibrogenic Lab Invest 83 2003 655 663
92. V.A. Fadok, D.L. Bratton, A. Konowal, P.W. Freed, J.Y. Westcott, and P.M. Henson Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF J Clin Invest 101 1998 890 898
93. I.A. Leclercq, G.C. Farrell, R. Schriemer, and G.R. Robertson Leptin is essential for the hepatic fibrogenic response to chronic liver injury J Hepatol 37 2002 206 213
94. P. Angulo, L.M. Alba, L.M. Petrovic, L.A. Adams, K.D. Lindor, and M.D. Jensen Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease J Hepatol 41 2004 943 949
95. R. Bataller, R.F. Schwabe, Y.H. Choi, L. Yang, Y.H. Paik, and J. Lindquist NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis J Clin Invest 112 2003 1383 1394
96. J.A. Oben, T. Roskams, S. Yang, H. Lin, N. Sinelli, and Z. Li Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice Biochem Biophys Res Commun 308 2003 284 292
97. V. Paradis, G. Perlemuter, F. Bonvoust, D. Dargere, B. Parfait, and M. Vidaud High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis Hepatology 34 2001 738 744
98. C.P. Day The potential role of genes in nonalcoholic fatty liver disease Clin Liver Dis 8 2004 673 691 [xi]
99. J. Ludwig, R.T. Viggiano, D.B. McGill, and B.J. Ott Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease Mayo Clin Proc 55 1980 434 438
100. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). J Am Med Assoc 2001;285:2486-97.
101. M. Palmer, and F. Schaffner Effect of weight reduction on hepatic abnormalities in overweight patients Gastroenterology 99 1990 1408 1411
102. T. Ueno, H. Sugawara, K. Sujaku, O. Hashimoto, R. Tsuji, and S. Tamaki Therapeutic effects of restricted diet and exercise in obese patients with fatty liver J Hepatol 27 1997 103 107
103. A. Franzese, P. Vajro, A. Argenziano, A. Puzziello, M.P. Iannucci, and M.C. Saviano Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population Dig Dis Sci 42 1997 1428 1432
104. M. Kugelmas, D.B. Hill, B. Vivian, L. Marsano, and C.J. McClain Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E Hepatology 38 2003 413 419
105. S.A. Harrison, C. Fincke, D. Helinski, S. Torgerson, and P. Hayashi A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients Aliment Pharmacol Ther 20 2004 623 628
106. T. Sabuncu, Y. Nazligul, M. Karaoglanoglu, E. Ucar, and F.B. Kilic The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis Rom J Gastroenterol 12 2003 189 192
107. J.G. Kral, S.N. Thung, S. Biron, F.S. Hould, S. Lebel, and S. Marceau Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis Surgery 135 2004 48 58
108. J. Castillo, E. Fabrega, C.F. Escalante, J.C. Sanjuan, L. Herrera, and F. Hernanz Liver transplantation in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity Obes Surg 11 2001 640 642
109. E.M. Silverman, J.A. Sapala, and H.D. Appelman Regression of hepatic steatosis in morbidly obese persons after gastric bypass Am J Clin Pathol 104 1995 23 31
110. J.B. Dixon, P.S. Bhathal, N.R. Hughes, and P.E. O'Brien Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss Hepatology 39 2004 1647 1654
111. A. Uygun, A. Kadayifci, A.T. Isik, T. Ozgurtas, S. Deveci, and A. Tuzun Metformin in the treatment of patients with non-alcoholic steatohepatitis Aliment Pharmacol Ther 19 2004 537 544
112. S. Nair, A.M. Diehl, M. Wiseman, G.H. Farr Jr, and R.P. Perrillo Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial Aliment Pharmacol Ther 20 2004 23 28
113. E. Bugianesi, E. Gentilcore, R. Manini, S. Natale, E. Vanni, and N. Villanova A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease Am J Gastroenterol 100 2005 1082 1090
114. J.B. Schwimmer, M.S. Middleton, R. Deutsch, and J.E. Lavine A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis Aliment Pharmacol Ther 21 2005 871 879
115. K. Promrat, G. Lutchman, G.I. Uwaifo, R.J. Freedman, A. Soza, and T. Heller A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 2004 188 196
116. B.A. Neuschwander-Tetri, E.M. Brunt, K.R. Wehmeier, D. Oliver, and B.R. Bacon Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 2003 1008 1017
117. J. Laurin, K.D. Lindor, J.S. Crippin, A. Gossard, G.J. Gores, and J. Ludwig Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study Hepatology 23 1996 1464 1467
118. P. Vajro, A. Franzese, G. Valerio, M.P. Iannucci, and N. Aragione Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children J Pediatr 136 2000 739 743
119. K.D. Lindor, K.V. Kowdley, E.J. Heathcote, M.E. Harrison, R. Jorgensen, and P. Angulo Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 39 2004 770 778
120. J.E. Lavine Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study J Pediatr 136 2000 734 738
121. S.A. Harrison, S. Torgerson, P. Hayashi, J. Ward, and S. Schenker Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis Am J Gastroenterol 98 2003 2485 2490
122. K. Carson, M.K. Washington, W.R. Treem, P.A. Clavien, and C.M. Hunt Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient Liver Transpl Surg 3 1997 174 176
123. R.M. Molloy, R. Komorowski, and R.R. Varna Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation Liver Transpl Surg 3 1997 177 178
124. W.R. Kim, J.J. Poterucha, M.K. Porayko, E.R. Dickson, J.L. Steers, and R.H. Wiesner Recurrence of nonalcoholic steatohepatitis following liver transplantation Transplantation 62 1996 1802 1805
125. A.B. Czaja Recurrence of nonalcoholic steatohepatitis after liver transplantation Liver Transpl Surg 3 1997 185 186
126. A. Burke, and M.R. Lucey Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation Am J Transplant 4 2004 686 693